Posted by Michael Wonder on 31 Mar 2021
Ontozry (cenobamate) receives European Commission approval for the treatment of drug resistant focal onset seizures in adults
30 March 2021 - SK Biopharmaceuticals and Angelini Pharma will collaborate to launch the treatment in countries in the European Economic Area.
SK Biopharmaceuticals announced today that cenobamate received marketing authorisation from the European Commission under the brand name Onotzry for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.
